Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Jiangsu Nanfang Medical Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 0.87%.
Jiangsu Nanfang Medical Co (SHSE:603880) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Nanfang Medical Co (SHSE:603880) has a ROCE % of 0.87% as of Mar. 2026.
Is Jiangsu Nanfang Medical Co's ROCE % too high?
Jiangsu Nanfang Medical Co's current ROCE % is 0.87%. The Medical Devices & Instruments industry median ROCE % is 2.30. Jiangsu Nanfang Medical Co's value of 0.87% is 62.1% below this industry median. Overall, Jiangsu Nanfang Medical Co has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Nanfang Medical Co's ROCE % compare to ISRG and BDX?
Jiangsu Nanfang Medical Co's ROCE % of 0.87% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.30. Jiangsu Nanfang Medical Co's value of 0.87% is 62.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.30, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Nanfang Medical Co's current ROCE % of 0.87% is 62.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Nanfang Medical Co's current ROCE % is 0.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Nanfang Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Nanfang Medical Co (SHSE:603880) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.71, compared to a current price of ¥6.37 — trading 35.2% above its estimated fair value. The current ROCE % is 0.87% and 62.1% below the Medical Devices & Instruments industry median of 2.30. Jiangsu Nanfang Medical Co's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Jiangsu Nanfang Medical Co (SHSE:603880), the current ROCE % is 0.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Nanfang Medical Co (SHSE:603880) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Nanfang Medical Co stock appears to be overvalued.
The current stock price of ¥6.37 is trading 35.2% above its estimated GF Value™ of ¥4.71.
GuruFocus considers Jiangsu Nanfang Medical Co to be Significantly Overvalued.
Key valuation signals for SHSE:603880:
ROCE %: 0.87%
GF Value™: ¥4.71 vs. price of ¥6.37 (35.2% above fair value)
Industry Position: 62.1% below the Medical Devices & Instruments median
No single metric tells the full story. See the SHSE:603880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Nanfang Medical Co Ltd is a domestic adhesive dressing production enterprise that integrates research and development, production, and sales. It produces a band-aid in China. The company is focused on the development of self-owned brand products such as first-aid kits, sports protection products, and care products on the basis of the original series of Miaoshou medical dressings.
50GF Score
Get the complete analysis for SHSE:603880
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603880 has been successfully added to your 
